stockrowQuantum Cyber N.V
QUCY Healthcare Diagnostics & Research
Quantum Cyber N.V’s revenue for fiscal 2025 (year ended December 2025) was $537,100.00, down 39.9% from fiscal 2024.
- EPS
- +96.0%
- Free cash flow
- +26.7%
Quarter to June 2026, against a year earlier
Follow QUCY
Alert me
Quantum Cyber N.V (QUCY) EV/Sales
As of 5 November 2026, Quantum Cyber N.V (QUCY) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from 0.0× (December 2022) to 162× (January 2023); the current reading is higher than 23% of that period. That is below the Diagnostics & Research industry median of 5.2× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.3× | (38.63%) |
| FY2024 | 8.6× | (57.33%) |
| FY2023 | 20.1× | (86.20%) |
| FY2022 | 146× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2023 | 20.1× | (59.20%) |
| Sep 2023 | 49.4× | (41.90%) |
| Jun 2023 | 85.0× | (30.55%) |
| Mar 2023 | 122× | (16.17%) |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QUCY Quantum Cyber N.V | 0.8× |
| MDXH MDxHealth SA compare | 0.8× |
| FLGT Fulgent Genetics, Inc. compare | 0.8× |
| PRPO Precipio, Inc. compare | 1.2× |
| BDSX Biodesix, Inc. compare | 2.2× |
| XGN Exagen Inc. compare | 2.6× |
| BNR Burning Rock Biotech Limited Sponsored ADR compare | 18.6× |
| MDXHF MedX Health Corp. compare | 29.4× |
| IMDX Insight Molecular Diagnostics Inc. compare | 43.0× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)